Use of vasopressors for septic shock in the neonatal intensive care unit

J Perinatol. 2023 Oct;43(10):1274-1280. doi: 10.1038/s41372-023-01667-8. Epub 2023 Apr 13.

Abstract

Objective: To describe outcomes for infants in the neonatal intensive care unit with septic shock based on the vasopressor administered.

Methods: This is a multicenter cohort study of infants with an episode of septic shock. We evaluated the primary outcomes of mortality and pressor-free days alive in the first week after shock using multivariable logistic and Poisson regressions.

Results: We identified 1592 infants. Mortality was 50%. Dopamine was the most used vasopressor (92% of episodes) and hydrocortisone was co-administered with a vasopressor in 38% of episodes. Compared to infants treated with dopamine alone, adjusted odds of mortality were significantly higher for those treated with epinephrine alone (aOR 4.7 [95% CI: 2.3-9.2]). Adjuvant hydrocortisone was associated with significantly lower adjusted odds of mortality (aOR 0.60 [0.42-0.86]) CONCLUSIONS: The use of epinephrine as either a solo agent or in combination therapy was associated with significantly worse outcomes, while adjuvant hydrocortisone was associated with decreased mortality.

Publication types

  • Multicenter Study

MeSH terms

  • Cohort Studies
  • Dopamine / therapeutic use
  • Epinephrine / therapeutic use
  • Humans
  • Hydrocortisone / therapeutic use
  • Infant, Newborn
  • Intensive Care Units
  • Intensive Care Units, Neonatal
  • Retrospective Studies
  • Shock, Septic* / complications
  • Shock, Septic* / drug therapy
  • Vasoconstrictor Agents / therapeutic use

Substances

  • Hydrocortisone
  • Dopamine
  • Vasoconstrictor Agents
  • Epinephrine